EU Launches Antitrust Probe into Align Technology Over Invisalign Sales Tactics
ALGN sits 38% above its 52-week low of $122.
Summary
The European Union's antitrust body has launched a formal investigation into Align Technology, the maker of Invisalign. The probe will assess whether the company leveraged its dominant position with Invisalign to compel dentists to purchase its iTero intra-oral scanners, potentially violating EU competition rules. This is the first such investigation in the medical-devices sector by the European Commission, signaling a significant regulatory risk that could lead to substantial fines or changes to Align's sales strategy in a critical market.
At the time of this announcement, ALGN was trading at $168.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $122.00 to $208.31. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.